A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps



Status:Completed
Conditions:Sinusitis
Therapuetic Areas:Otolaryngology
Healthy:No
Age Range:18 - 75
Updated:4/6/2019
Start Date:November 21, 2017
End Date:March 7, 2019

Use our guide to learn which trials are right for you!

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Clinical Trial of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps

The purpose of this study is to determine the efficacy and safety of omalizumab compared with
placebo in adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who have had
an inadequate response to standard-of-care treatments.


Inclusion Criteria:

- Age 18-75 years, inclusive, at time of signing Informed Consent Form.

- Ability to comply with the study protocol, in the investigator's judgment.

- Nasal polyp score (NPS) >= 5, with a unilateral score of >= 2 for each nostril, at
screening (Day -35), and on Day -7.

- Sino-Nasal Outcome Test-22 (SNOT-22) score >=20 at screening (Day -35) and at
randomization (Day 1).

- Treatment with at least nasal mometasone 200 micro gram per day, or equivalent daily
dosing of nasal corticosteroid (CS), for at least 4 weeks before screening (Day -35).

- Treatment with nasal mometasone 200 micro gram twice a day (BID) (or once a day [QD]
if intolerant to twice daily) during the run-in period with an adherence rate of at
least 70%.

- Presence of nasal blockage/congestion with NCS >=2 (1-week recall) at Day -35 and an
average of the daily NCS score over the 7 days prior to randomization of NCS >1 with
at least one of the following symptoms prior to screening: nasal discharge
(anterior/posterior nasal drip) and/or reduction or loss of smell.

- Eligibility per the study drug dosing table

- Willingness to maintain all background medications stable for the duration of the
treatment and follow-up periods.

- Willingness and ability to use electronic device to enter study-related information in
electronic devices (electronic diary [eDiary]/electronic tablet [eTablet]).

- Demonstration of at least 70% adherence to eDiary daily symptom assessment during run
in period, with fully completed entries on at least 4 days in the week prior to
randomization.

- For women of childbearing potential: agreement to remain abstinent (refrain from
heterosexual intercourse) or use acceptable contraceptive methods during the treatment
period and for 60 days after the last dose of study drug.

Exclusion Criteria:

- Known history of anaphylaxis/hypersensitivity to omalizumab.

- Treatment with investigational drugs within 12 weeks or 5 half-lives (whichever is
longer) prior to screening (Day -35).

- Treatment with monoclonal antibodies (e.g., omalizumab, mepolizumab) for 6 months
prior to screening (Day -35).

- Current treatment with leukotriene antagonists/modifiers, unless participant has been
on stable dosing of such medication for at least 1 month prior to screening (Day -35).

- Treatment with non-steroid immunosuppressants within 2 months or 5 half-lives,
whichever is longer, prior to screening (Day -35).

- Treatment with systemic corticosteroids, except when used as treatment for nasal
polyposis, within 2 months prior to screening (Day -35).

- Usage of systemic CS during the run-in period. Participants requiring systemic CS
during run-in may be rescreened after completing systemic CS.

- Treatment with intranasal CS drops or CS administering devices (e.g., OptiNose device
or stents) within 1 month prior to screening (Day -35) or during the run-in period.

- History of nasal surgery (including polypectomy) within 6 months prior to screening.

- History of sinus or nasal surgery modifying the structure of the nose such that
assessment of NPS is not possible.

- Uncontrolled epistaxis requiring surgical or procedural intervention, including nasal
packing, within 2 months prior to screening.

- Known or suspected diagnosis of cystic fibrosis, primary ciliary dyskinesia (e.g.,
Kartagener syndrome) or other dyskinetic ciliary syndromes, hypogammaglobulinemia or
other immune deficiency syndrome, chronic granulomatous disease and granulomatous
vasculitis, granulomatosis with polyangiitis (e.g., Wegener's Granulomatosis), or
eosinophilic granulomatous with polyangiitis (EGPA) (e.g., Churg-Strauss syndrome).

- Presence of antrochoanal polyps.

- Concomitant conditions that interfere with evaluation of primary endpoint:

- Nasal septal deviation occluding one or both nostrils.

- Ongoing rhinitis medicamentosa.

- Acute sinusitis, nasal infection, or upper respiratory infection during the
run-in period.

- Known or suspected invasive or expansive fungal rhinosinusitis.

- Known HIV infection at screening.

- Known acute and chronic infections with hepatitis C virus (HCV) and hepatitis B virus
(HBV) at screening.

- History of myocardial infarction, unstable angina, cerebrovascular accident, or
transient ischemic attack or a known history of a hypercoagulable disorder

- Active tuberculosis requiring treatment within 12 months prior to screening (Day -35).

- Initiation of or change in allergen immunotherapy within 3 months prior to screening
(Day -35) or during the run-in period.

- Initiation of or change in aspirin desensitization within 4 months prior to screening
(Day -35) or during the run-in period.

- Pregnant or breastfeeding, or intending to become pregnant during the study or within
60 days after the last dose of omalizumab.

- Current malignancy or history of malignancy within 5 years prior to screening, except
for appropriately treated carcinoma in situ of the cervix or non-melanoma skin
carcinoma that has been treated or excised and is considered resolved.

- Any serious medical condition (including but not limited to significant arrhythmia,
uncontrolled hypertension, significant pulmonary disease other than asthma) or
abnormality in clinical laboratory tests that precludes the participant's safe
participation in and completion of the study.

- History of alcohol, drug, or chemical abuse within 6 months of screening.
We found this trial at
17
sites
Birmingham, Alabama 35209
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Norfolk, Virginia 23507
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
4202 E Fowler Ave
Tampa, Florida 33620
(813) 974-2011
University of South Florida The University of South Florida is a high-impact, global research university...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Baltimore, Maryland 21236
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Boerne, Texas 78006
?
mi
from
Boerne, TX
Click here to add this to my saved trials
Chevy Chase, Maryland 20815
?
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Colorado Springs, Colorado 80909
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
?
mi
from
Columbia, MO
Click here to add this to my saved trials
185 De Pintelaan
Gent, 9000
?
mi
from
Gent,
Click here to add this to my saved trials
1490 West 49th Place
Hialeah, Florida 33012
?
mi
from
Hialeah, FL
Click here to add this to my saved trials
3901 Rainbow Blvd
Kansas City, Kansas 66160
(913) 588-5000
University of Kansas Medical Center The University of Kansas Medical Center serves Kansas through excellence...
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
6327 Southeast Milwaukie Avenue
Portland, Oregon 97202
?
mi
from
Portland, OR
Click here to add this to my saved trials
Rancho Cordova, California 95762
?
mi
from
Rancho Cordova, CA
Click here to add this to my saved trials
San Antonio, Texas 78251
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Stockton, California 95207
?
mi
from
Stockton, CA
Click here to add this to my saved trials
?
mi
from
Tucson, AZ
Click here to add this to my saved trials